Google (NASDAQ: GOOGL) is set to pay its quarterly dividend to shareholders on September 15.

Nio stock price could be on the cusp of a strong bullish breakout after forming a highly bullish pattern and, as the CEO touts the upcoming “harvest season” when it starts to realize the returns of the recent investments. It was trading at $4.8 on Friday, up sharply from the year-to-date low of $3.

Cybersecurity is "not a nice to have, it's a have to have," says Nathaniel Bradley. Ahead of Palo Alto Networks' (PANW) earnings after the close on Monday, he called the company the "tip of the spear" in the industry.

Hedge funds invest in Microsoft, UnitedHealth and homebuilders. ETFs like MAGS, IHF and XHB let you invest like billionaires.

TLN, CYD and MGIC made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on August 18, 2025.

PDD Holdings Inc. Sponsored ADR (PDD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Heico (HEI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

SHANGHAI and NEW YORK, Aug. 18, 2025 (GLOBE NEWSWIRE) -- TH International Limited (“Tims China” (Nasdaq: THCH)), the exclusive operator of Tim Hortons coffee shops in China, plans to release its second quarter 2025 financial results before the U.S. market opens on Tuesday, August 26, 2025, with a conference call to follow at 8:00 AM EST or 8:00 PM China Standard Time. The conference call will be webcast, and can be accessed on the Company's Investor Relations website at https://ir.timschina.com/events-presentations/presentations-webcasts.

S&P 500 holds steady as traders await Powell's Jackson Hole speech and major retail earnings. Fed rate cut bets now sit at 85%, raising anticipation.

PSX has reduced gasoline output at its Bayway refinery after a fire disrupted operations at a key unit.

atai Life Sciences (ATAI) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

The mean of analysts' price targets for Brainsway (BWAY) points to a 25.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

The average of price targets set by Wall Street analysts indicates a potential upside of 77.3% in Enovis (ENOV). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

The average of price targets set by Wall Street analysts indicates a potential upside of 45.6% in CorMedix (CRMD). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

TPG RE Finance Trust, Inc. (TRTX) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, TRTX's 50-day simple moving average crossed above its 200-day simple moving average, known as a "golden cross.

Dorman Products, Inc. (DORM) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, DORM's 50-day simple moving average broke out above its 200-day moving average; this is known as a "golden cross.

The average of price targets set by Wall Street analysts indicates a potential upside of 106.2% in XOMA Royalty (XOMA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

The average of price targets set by Wall Street analysts indicates a potential upside of 149.7% in Mineralys Therapeutics, Inc. (MLYS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

The consensus price target hints at a 26.7% upside potential for Kiniksa Pharmaceuticals International, plc (KNSA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

The consensus price target hints at a 101% upside potential for Rapt Therapeutics (RAPT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.